Plasma and urinary concentrations of 5-aminolevulinic acid (5-ALA) and its metabolites after oral administration of 5-ALA hydrochloride in healthy subjects.

Not Applicable

• Conditions: Healthy volunteers

• Registration Number: JPRN-UMIN000019168
• Lead Sponsor: Hiroshima University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2015-10-01
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 120

Inclusion Criteria

Not provided

Exclusion Criteria

1) History of cancer diagnosis 2) Participation in any clinical trial within 90 days of the commencement of the trial 3) Pregnant or nursing a child 4) Cardiac, renal, and/or hepatic dysfunction 5) History of severe disease and/or major surgery 6) History of hypersensitivity caused by 5-aminolevulinic acid or porphyrin 7) Porphyria 8) Severe anemia 9) Taking drugs or functional food that may cause photosensitivity (e.g. tetracycline antibiotics, sulfonamides, new quinolone antibacterial agents, Hypericum perforatum, and so on)

Study & Design

• Study Type: Interventional
• Study Design: Not specified